Huntington’s Disease

Jang-Ho J. Cha and Anne B. Young



REFERENCES

    Albin RL and Greenamyre JT (1992). Alternative excitotoxic hypotheses. Neurology 42:733-738.

    Albin RL, Reiner A, Anderson KD, D'Amato CJ, Penney JB, and Young AB (1988). Juvenile onset Huntington's disease: Two cases studied with immunocytochemistry, cholinesterase histochemistry, and autoradiography. Neurology 38:360.

    Albin Rl, Reiner A, Anderson KD, Dure LS, Handelin B, Balfour R, Whetsell WO, Jr., Penney JB, and Young AB (1992). Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31:425-430.

    Albin RL, Reiner A, Anderson KD, Penney JB, and Young AB (1990). Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27:357-365.

    Albin RL, Young AB, and Penney JB (1989). The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:366-375.

    Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M, Wasmuth J, Buckler A, Church D, Housman D, Berks M, Micklem G, Durbin R, Dodge A, Read A, Gusella J, and Macdonald ME (1994). Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat. Somat.Cell Mol.Genet. 20:27-38.

    Antonini A, Leenders KL, Spiegel R, Meier D, Vontobel P, Weigell-Weber M, Sanchez-Pernaute R, De Yebenez JG, Boesiger P, Weindl A, and Maguire RP (1996). Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119:2085-2095.

    Aronin N, Chase K, Young C, Sapp E, Schwarz C, Matta N, Kornreich R, Landwehrmeyer B, Bird E, Beal MF, Vonsattel JP, Smith T, Carraway R, Boyce FM, Young AB, Penney JB, and DiFiglia M (1995). CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain. Neuron 15:1193-1201.

    Augood SJ, Faull RLM, and Emson PC (1997). Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42:215-221.

    Augood SJ, Faull RLM, Love DR, and Emson PC (1996). Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72:1023-1036.

    Avila-Giron R (1973). Medical and social aspects of Huntington's chorea in the state of Zulia, Venezuela. Adv. Neurol. 1:261-266.

    Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, Dawson VL, and Dawson TM (1996). Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc. Natl. Acad. Sci. (USA) 93:5037-5042.

    Barbeau A, Chase TN, and Paulson GW, Eds. (1973). Huntington's chorea 1872-1972. Advances in Neurology. New York, Raven Press.

    Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, and Hyman BT (1993a). Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61:1147-1150.

    Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, and Hyman BT (1993b). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionaic acid. J. Neurosci. 13:4181-4192.

    Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, and Martin JB (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171.

    Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, and Ross CA (1998). Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis 4:387-97.

    Bittigau P and Ikonomidou C (1997). Glutamate in neurologic diseases. J Child Neurol 12:471-485.

    Block-Galarza J, Chase KO, Sapp E, Vaughan KT, Vallee RB, DiFiglia M, and Aronin N (1997). Fast transport and retrograde movement of huntingtin and HAP1 in axons. NeuroReport 8:2247-2251.

    Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, and Beal MF (1998). Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. J Neurochem 71:2642-4.

    Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, and Sanberg PR (1995). Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats. Brain ResearchBull. 36:549-556.

    Boutell JM, Wood JD, Harper PS, and Jones AL (1998). Huntingtin interacts with cystathionine beta-synthase. Hum. Mol. Genet. 7:371-8.

    Brennan WA, Bird ED, and Aprille JR (1985). Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44:1948-1950.

    Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, and Beal MF (1993). Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60:356-359.

    Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MMK, Bird ED, and Beal MF (1997). Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulneralbility of the basal ganglia. Ann. Neurol. 41:646-653.

    Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM, and Strittmatter WJ (1996a). Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat. Med. 2:347-350.

    Burke JR, Enghild JJ, Martin ME, Jou YS, Myers RM, Roses AD, Vance JM, and Strittmatter WJ (1996b). Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH [see comments]. Nat Med 2:347-50.

    Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, and Orr HT (1995). SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82:937-948.

    Butterworth J, Yates CM, and Reynolds GP (1985). Distribution of phosphate activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci. 67:161-171.

    Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, and Young AB (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. (USA) 95:6480-6485.

    Choi DW, Lobner D, and Dugan LL (1998). Glutamate receptor-mediated neuronal death in the ischemic brain. Ischemic Stroke: from Basic Mechanisms to New Drug Development. CY Hsu. Basel, Karger. 16:2-13.

    Choi DW and Rothman SM (1990). The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:171-182.

    Conneally PM (1984). Huntington disease: genetics and epidemiology. Am.J.Hum.Genet. 36:506-526.

    Cudkowicz M and Kowall NW (1990). Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol. 27:200-204.

    David G, Abbas N, Stevanin G, Dürr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel J-L, and Brice A (1997). Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat. Genet. 17:65-70.

    Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, and Bates GP (1998). Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351:131-133.

    Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, and Bates GP (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-48.

    de la Monte SM, Vonsattel J-P, and Richardson Jr. EP (1988). Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47:516-525.

    DiFiglia M (1990). Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci. 13:286-289.

    DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattell J-P, Carraway R, Reeves SA, Boyce FM, and Aronin N (1995). Huntingtin is a cytoplasmic protein asociated with vesicles in human and rat brain neurons. Neuron 14:1075-1081.

    DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, and Aronin N (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.

    Dragatsis I, Efstratiadis A, and Zeitlin A (1998). Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125:1529-39.

    Dragunow M, Faull RLM, Lawlor P, Beilharz EJ, Singleton K, Walker EB, and Mee E (1995). In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. neuroreport 6:1053-1057.

    Durbach N and Hayden MR (1993). George Huntington: The man behind the eponym. J Med Genet. 30:406-409.

    Dure LS, IV, Young AB, and Penney JB (1991). Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease. Ann. Neurol. 30:785-793.

    Duyao MP, Ambrose CM, Myers RH, Novoletto A, Persichetti F, Frontali M, Folstein SE, Ross C, Franz ML, Abbott M, Gray J, Conneally PM, Young A, Penney J, Hollingsworth Z, Shoulson I, Lazzarini AM, Falek A, Koroshetz W, Sax DS, Bird E, Vonsattel JP, Bonilla E, Alvir J, Bickham Conde J, Cha J-H, Dure L, Gomez F, Ramos M, Sanchez-Ramos J, Snodgrass SR, de Young M, Moscowitz C, Penchaszadeh G, MacFarlane H, Anderson MA, Jenkins B, Srinidhi J, Barnes G, Gusella JF, and MacDonald ME (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4:387-392.

    Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, and MacDonald ME (1998). Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7:1463-74.

    Fagg GE, Foster AC, and Ganong AH (1986). Excitatory amino acid synaptic mechanisms and neurological function. Trends Pharmacol. Sci. ?:357-363.

    Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, and Shoulson I (1996). Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. 11:321-323.

    Ferrante RJ, Beal MF, Kowall NW, Richardson EP, and Martin JB (1987a). Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 411:162-166.

    Ferrante RJ, Gutekunst CA, Persichetti F, McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, and Hersch SM (1997). Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J Neurosci 17:3052-63.

    Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, and Richardson EP (1987b). Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J.Neuropathol.Experimental Neurology 46(1):12-27.

    Folstein S (1989). Huntington's disease: A disorder of families. Baltimore, Johns Hopkins University Press.

    Gerber H-P, Seipel K, Georgiev O, Höfferer M, Hug M, Rusconi S, and Schaffner W (1994). Transcriptional activation modulated by homopolymeric glutamine and proline stretches. Science 263:808-811.

    Goff DC and Wine L (1997). Glutamate in schizophrenia:  clinical and research implications. Schizophr Res 27:157-168.

    Goldberg YP, Kremer B, Andrew SE, Theilmann J, Graham RK, Squitieri F, Telenius H, Adam S, Sajoo A, Starr E, Heiberg A, Wolff G, and Hayden MR (1993). Molecular analysis of new mutations for Huntington's disease: Intermediate alleles and sex of origin effects. Nat. Genet. 5:174-179.

    Goldberg YP, McMurray CT, Zeisler J, Almqvist E, Sillence D, Richards F, Gacy AM, Buchanan J, Telenius H, and Hayden MR (1995). Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Hum. Mol. Genet. 4:1911-8.

    Graybiel AM (1990). Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:244-254.

    Greene JG and Greenamyre JT (1995). Characterization of the excitotoxic potential of the reversible succinate dehydrogenase inhibitor malonate. J. Neurochem. 64:430-436.

    Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, and Schapira AHV (1996). Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39:385-389.

    Gusella JF, Tanzi RE, Bader PI, Phelan MC, Stevenson R, Hayden MR, Hofman KJ, Faryniarz AG, and Gibbons K (1985). Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolf-Hirschhorn syndrome. Nature 318:75-78.

    Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY, Young AB, Shoulson I, Bonilla E, and Martin JB (1983). A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306:234-238.

    Gutekunst C-A, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, and Hersch SM (1995a). Identification and localization of huntingtin in brain and human lymphoblatoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. (USA) 92:8710-8714.

    Gutekunst CA, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden JJ, and Hersch SM (1995b). Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 92:8710-4.

    Harper PS, Ed. (1996). Huntington's Disease. Major Problems in Neurology. Philadelphia, W. B. Saunders Co.

    Hayden MR (1981). Huntington's Chorea. New York, Springer-Verlag.

    Hedreen JC and Folstein SE (1995). Early loss of neostriatal striosome neurons in Huntington's disease. J Neuropathol.Experimental Neurology 54:105-120.

    Hedreen JC, Peyser CE, Folstein SE, and Ross CA (1991). Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133:257-261.

    Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, and Beal MF (1994). Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. 647:161-166.

    Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche CM, Rubin EM, and Hayden MR (1996). Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum. Mol. Genet. 5:1875-1885.

    Huntington G (1872). On chorea. Medical and Surgical Report 1872 26:317-321.

    Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is unstable in Huntington's disease chromosomes. Cell 72:971-983.

    Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, and Kakizuka A (1996). Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 13:196-202.

    James CM, Houlihan GD, Snell RG, Cheadle JP, and Harper PS (1994). Late-onset Huntington's disease: a clinical and molecular study. Age Ageing 23:445-8.

    Jenkins BG, Koroshetz WJ, Beal MF, and Rosen BR (1993). Evidence for impairment of energy metabolisn in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43:2689-2695.

    Kahlem P, Green H, and Djian P (1998). Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1:595-601.

    Kahlem P, Terré C, Green H, and Djian P (1996). Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl. Acad. Sci. (USA) 93:14580-14585.

    Karlin S and Burge C (1996). Trinucleotide repeats and long homopeptides in genes and proteins associated with nervous system disease and development. Proc. Natl. Acad. Sci. (USA) 93:1560-1565.

    Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, and et al. (1994). CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 [see comments]. Nat Genet 8:221-8.

    Kawaguchi Y, Wilson CJ, Augood SJ, and Emson PC (1995). Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci. 18:527-535.

    Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme C, Claude K, Sotack J, Greenamyre JT, Dunn C, and Shoulson I (1996). A controlled trial of remacemide hydrochloride in Huntington's disease. Mov. Disord. 11:273-277.

    Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, and DiFiglia M (1999). Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 19:964-73.

    Klockgether T and Turski L (1993). Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol. 34:585-593.

    Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M, Tomoda A, Miike T, Naito H, Ikuta F, and Tsuji S (1994). Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat. Genet. 6:9-13.

    Kornbuber J and Wiltfang J (1998). The role of glutamate in dementia. J Neural Transm 53:277-287.

    Koroshetz WJ, Jenkins BG, Rosen BR, and Beal MF (1997). Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 41:160-165.

    Kosinski CM, Cha JH, Young AB, Persichetti F, MacDonald M, Gusella JF, Penney JB, and Standaert DG (1997). Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp. Neurol. 144:239-247.

    Kuhl DE, Markham CH, Metter EJ, Riege WH, Phelps ME, and Mazziotta JC (1985). Local cerebral glucose utilization in symptomatic and presymptomatic Huntingtons disease. Brain Img.Brain Func. 2:199-209.

    La Spada AR, Wilson EM, Lubahn DB, Harding AE, and Fischbeck KH (1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-9.

    Landwehrmeyer GB, McNeil SM, Dure LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E, De Young M, Avila-Gonzales AJ, Wexler NS, DiFiglia M, Gusella JF, Macdonald ME, Penney JB, Young AB, and Vonsattel JP (1995). Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals. Ann. Neurol. 37:218-230.

    Leeflang EP, Zhang L, Tavare S, Hubert R, Srinidhi J, Macdonald ME, Myers RH, De Young M, Wexler NS, Gusella JF, and Arnheim N (1995). Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: Quantification of the mutation frequency spectrum. Hum. Mol. Genet. 4:1519-1526.

    Li SH, Schilling G, Young WS, III, Li XJ, Margolis RL, Stine OC, Wagster MV, Abbott MH, Franz ML, Ranen NG, Folstein SE, Hedreen JC, and Ross CA (1993). Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:985-993.

    Li XJ, Sharp AH, Li SH, Dawson TM, Snyder SH, and Ross CA (1996). Huntingtin-associated protein (HAP1): Discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proceedings of the National Academy of Sciences, U.S.A.. 93:4839-4844.

    London ED, Yamamura HI, Bird ED, and Coyle JT (1981). Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease. Biol. Psychiatry 16:155-162.

    Lorand L (1996). Neurodegenerative diseases and transglutaminase. Proc. Natl. Acad. Sci. (USA) 93:14310-14313.

    MacDonald ME, Barnes G, Srinidhi J, Duyao MP, Ambrose CM, Myers RH, Gray J, Conneally PM, Young A, Penney J, Shoulson I, Hollingsworth Z, Koroshetz W, Bird E, Vonsattel JP, Bonilla E, Moscowitz C, Penchaszadeh G, Brzustowicz L, Alvir J, Bickham Conde J, Cha JH, Dure L, and Gomez F (1993). Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30:982-986.

    Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, and Bates GP (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506.

    Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, and Schapira AH (1990). Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336:749.

    Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffman JM, Kuhl DE, Lanto AB, Wapenski JA, and Markham CH (1987). Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N. Engl. J. Med. 316:357-362.

    Myers RH, Macdonald ME, Koroshetz WJ, Duyao MP, Ambrose CM, Taylor SAM, Barnes G, Srinidhi J, Lin CS, Whaley WL, Lazzarini AM, Schwarz M, Wolff G, Bird ED, Vonsattel JPG, and Gusella JF (1993). De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 5:168-173.

    Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, and Hayden MR (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823.

    Negrette A (1958). Corea de Huntington. Maracaibo, Venezuela, University of Zulia.

    Ordway JM, Tallaksen-Greene S, Gutekunst C-A, Bernstein EM, Cearley JA, Wiener HW, Dure IV LS, Lindsey R, Hersch SM, Jope RS, Albin RL, and Detloff PJ (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91:753-763.

    Orr HT, Chung MY, Banfi S, Kwiatkowski TJ, Jr., Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, and Zoghbi HY (1993). Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4:221-6.

    Palfi SP, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, and Hantraye P (1996). Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 16:3019-3025.

    Parker WD, Jr., Boyson SJ, Luder AS, and Parks JK (1990). Evidence for a defect in NADH:ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40:1231-1234.

    Patel J and Zinkand WC (1994). Role of metabotropic glutamate receptors in neuronal degeneration. The Metabotropic Glutamate Receptors. PJ Conn and J Patel. Totowa, NJ, Humana Press:231-242.

    Paulson HL and Fischbeck KH (1996). Trinucleotide repeats in neurogenetic disorders. Annu. Rev. Neurosci. 19:79-107.

    Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, and Pittman RN (1997). Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333-44.

    Penney JB, Jr., Vonsattel JP, MacDonald ME, Gusella JF, and Myers RH (1997). CAG repeat number governs the development rate of pathology in Huntington's disease [see comments]. Ann Neurol 41:689-92.

    Penney JB, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, Ramos-Arroyo M, Gomea F, Penchaszadeh G, Alvir J, Esteves J, DeQuiroz I, Marsol N, Moreno H, Conneally L, Bonilla E, and Wexler NS (1990). Huntington's Disease in Venezuela: 7 Years of Follow-up on Symptomatic and Asymptomatic Individuals. Mov. Disord. 5:93-99.

    Perry TL, Hansen S, and Kloster M (1973). Huntington's chorea:  deficiency of gamma-aminobutyric acid in brain. N. Engl. J. Med. 288:337-342.

    Persichetti F, Ambrose CM, Ge P, McNeil SM, Srinidhi J, Anderson MA, Jenkins B, Barnes GT, Duyao MP, Kanaley L, and et al. (1995). Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol Med 1:374-83.

    Perutz MF (1995). Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Mol Med 1:718-21.

    Perutz MF (1996). Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr. Opin. Struct. Biol. 6:848-858.

    Perutz MF, Johnson T, Suzuki M, and Finch JT (1994). Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. (USA) 91:5355-5358.

    Portera-Cailliau C, Hedreen JC, Price DL, and Koliatsos VE (1995). Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 15:3775-3787.

    Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen X-N, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, and Sahba S (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat. Genet. 14:269-276.

    Ranen NG, Peyser CE, and Folstein SE (1993). A Physician's Guide to the Management of Huntington's Disease: Pharmacologic and Non-Pharmacologic Interventions. New York, Huntington's Disease Society of America.

    Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Miller G, and Tagle DA (1998a). Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat. Genet. 20:198-202.

    Reddy PH, Williams M, Charles V, Garrett L, Pike-Buchanan L, Whetsell WO, Jr., Miller G, and Tagle DA (1998b). Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20:198-202.

    Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, and Young AB (1988). Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences U.S.A. 85:5733-5737.

    Richfield EK, O'Brien CF, Eskin T, and Shoulson I (1991). Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 132:121-126.

    Robinson MB and Coyle JT (1987). Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J. 1:446-455.

    Roizin L, Kaufman N, Wilson S, Stellar S, and Liu JC (1976). Neuropathologic observations in Huntington's chorea. Progress in Neuropathology III. HM Zimmerman. New York, Grune and Stratton:447-488.

    Roizin L, Stellar S, and Liu JC (1979). Neuronal nuclear-cytoplasmic changes in Huntington's chorea: electron microscope investigations. Advances in Neurology. TN Chase, NS Wexler and A Barbeau. New York, Raven Press. 23:95-122.

    Ross CA (1997). Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19:1147-1150.

    Saudou F, Finkbeiner S, Devys D, and Greenberg ME (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.

    Schapira AHV, Tabrizi SJ, Cleeter M, Xuereb J, and Cooper JM (1997). Biochemical abnormalities in Huntington's disease brain. 17th International Meeting of the World Federation of Neurology Research Group on Huntington's Disease, Syndey, Australia.

    Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, and Wanker EE (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549-58.

    Shoulson I (1998). Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 282:1072-1074.

    Sittler A, Walter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, Bates GP, Lehrach H, and Wanker EE (1998). SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell 2:427-36.

    Skinner PJ, Koshy B, Cummings CJ, Klement IA, Helin K, Servadio A, Zoghbi HY, and Orr HT (1997). Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389:971-974.

    Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, Macdonald ME, Gusella JF, Harper PS, and Shaw DJ (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4:393-397.

    Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz K, Collins FS, and Albin RL (1993). Widespread expression of the human and rat Huntington's disease gene in brain and nonneuronal tissues. Nat. Genet. 5:259-265.

    Taylor-Robinson SD, Weeks RA, Bryant DJ, Sargentoni J, Marcus CD, Harding AE, and Brooks DJ (1996). Proton magnetic resonance spectroscopy in Huntington's disease: Evidence in favour of the glutamate excitotoxic theory? Mov. Disord. 11:167-173.

    Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, Adam S, Greenberg C, Ives EJ, Clarke LA, and Hayden MR (1994). Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat. Genet. 6:409-414.

    Telenius H, Kremer HPH, Theilmann J, Andrew SE, Almqvist E, Anvret M, Greenberg C, Greenberg J, Lucotte G, Squitieri F, Starr E, Goldberg YP, and Hayden MR (1993). Molecular analysis of juvenile Huntington disease: The major influence on (CAG)n repeat length is the sex of the affected parent. Hum.Mol.Genet. 2:1535-1540.

    Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, and Steindler DA (1995). DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp. Neurol. 133:265-272.

    Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, and Richardson EP (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44:559-577.

    Wanker EE, Rovira C, Scherzinger E, Hasenbank R, Walter S, Tait D, Colicelli J, and Lehrach H (1997). HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6:487-495.

    Weeks RA, Piccini P, Harding AE, and Brooks DJ (1996). Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol. 40:49-54.

    Wexler NS, Rose EA, and Housman DE (1991). Molecular approaches to hereditary diseases of the nervous system:  Huntington's disease as a paradigm. Annu. Rev. Neurosci. 14:503-529.

    White JK, Auerbach W, Duyao MP, Vonsattel JP, Gusella JF, Joyner AL, and MacDonald ME (1997). Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 17:404-410.

    Wuellner U, Young AB, Penney JB, and Beal MF (1994). 3-nitropropionic acid toxicity in the striatum. J. Neurochem. 63:1772-1781.

    Young AB (1994). Huntington's disease: lessons from and for molecular neuroscience. The Neuroscientist preview issue:30-37.

    Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, and Penney JB (1988). NMDA receptor losses in putamen from patients with Huntington's disease. Science 241:981-983.

    Young AB, Penney JB, Starosta-Rubenstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, and Hichwa R (1986a). Pet scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20:296-303.

    Young AB, Shoulson I, Penney JB, Starosta S, Gomez F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, and Wexler NS (1986b). Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36:244-249.

    Young AB, Shoulson I, Penney JB, Starosta-Rubinstein, Gomex F, Travers H, Ramos-Arroyo MA, Snodgrass SR, Bonilla E, Moreno H, and Wexler NS (1986c). Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36:244-249.

    Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, and Efstratiadis A (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11:155-163.

    Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, and Lee CC (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the a1A-voltage-dependent calcium channel. Nat. Genet. 15:62-69.

    Zuhlke C, Riess O, Bockel B, Lange H, and Thies U (1993). Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum. Mol. Genet. 2:2063-7.

Return to Chapter

published 2000